CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 27 target
Drug / intervention
HMPL-453drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04290325
NCT04290325Phase 2Unknown
CompareCT.gov

A Phase II, Single Arm, Multicenter and Open Labelstudy Evaluating the Efficacy, Safety and Pharmacokinetics of HMPL-453 in Patient With Advanced Malignant Mesothelioma

Hutchison Medipharma Limited·interventional·Posted Feb 28, 2020·Updated Jun 16, 2020

In Brief

A Phase 2 clinical trial evaluating HMPL-453 for Advanced Malignant Mesothelioma. Targeting 27 participants across 1 site.

Detailed Summary

This is a phase II, single arm, multicenter and open-label study to evaluate the efficacy, safety and pharmacokinetic of HMPL-453 in patient with advanced Malignant Mesothelioma

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignant Mesothelioma
CountriesChina
Collaborators--

Timeline

Phase 2UnknownOverdue
2020202120222023202420252026
First PostedFeb 28, 2020
Enrollment StartDec 30, 2019
Primary CompletionNov 30, 2022
Study CompletionMar 17, 2023
TodayJul 1, 2026
Enrollment to primary: 2.9 yearsPosted 6.3 years ago

Interventions

HMPL-453drug

HMPL-453 tablet